Trump Administration Reschedules Marijuana, Removing 280E Tax Burden

Event summary

  • The Trump Administration reclassified marijuana from Schedule III under the Controlled Substances Act on December 18, 2025.
  • This reclassification does not legalize marijuana but removes the Section 280E tax burden.
  • The change allows for expanded medical marijuana research within the United States.
  • Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) publicly applauded the decision.

The big picture

The rescheduling of marijuana to Schedule III represents a significant, albeit limited, step towards broader cannabis reform in the United States. While it doesn't legalize the substance, the removal of the 280E tax burden provides a substantial financial boost to state-legal operators like Trulieve, potentially improving margins and enabling increased investment. The move also signals a shift in federal policy, albeit under a specific administration, and could spur further legislative and regulatory changes in the years ahead.

What we're watching

Financial Impact
The extent of Trulieve’s financial benefit from the removal of Section 280E will depend on its current profitability and reinvestment strategy, and may not be immediately apparent in earnings reports.
Research Velocity
The speed at which American universities and companies capitalize on the eased research restrictions will determine the long-term impact on product development and market differentiation within the cannabis sector.
Political Risk
Future administrations could reverse this rescheduling, creating ongoing uncertainty for cannabis operators and highlighting the vulnerability of the industry to political shifts.